Preservative Challenge Testing for Cosmetics: Screen vs Full Study
Do I need a preservative challenge test for my cosmetic? There is no single global yes-or-no rule. The answer depends on the product format and water availability, how the pack exposes the formula during use, the target market, the evidence already available and what the safety assessor or Responsible Person requires. A development screen can help compare formula candidates, while a full named-method study is intended for a defined product version. A low-risk exception, where a market allows one, still needs a documented scientific justification. Agree the evidence plan before quoting so the formula stage, method, sample and intended use of the report all match.
Two laboratories send quotations that both say "challenge test". One costs a fraction of the other and promises an answer sooner. It is tempting to treat them as the same service at two prices. Often they are not: one is a development screen, the other is a full study to a named method, and the reports they produce can be used for different things.
This guide is for brand owners and buyers commissioning preservative challenge testing through an external laboratory, usually alongside an OEM or ODM manufacturer. It helps you tell a screen from a full study, compare proposals on what they actually deliver and decide which one your project needs at each stage. It is not a microbiology method guide and does not restate ISO 11930 or any other standard. Choosing and verifying a laboratory is covered in our cosmetic testing laboratory guide, and the overall safety file in our cosmetic safety testing guide.
Quick answer
- A screen is a development tool: an early indication of whether a preservative system is heading in the right direction. It is useful for choosing between formula candidates.
- A full study here means a study run to a method the brand and laboratory have named and agreed, on a defined product version, with the controls and reporting that method calls for.
- They are not interchangeable. A screen "pass" should not be filed as a full named-method report, and a full study is still only one input to the safety assessment, not market approval.
- Compare scope before price: method and deviations, sample stage, grouped or individual results, recovery checks, report contents and intended use.
When Does a Cosmetic Need Preservative Challenge Testing?
Start with risk and intended use, then let the qualified laboratory and safety assessor choose the appropriate evidence. The same product name can lead to a different decision when the formula, pack, market or stage changes.
- Product type and water availability: water-rich emulsions and cleansers usually present a different microbiological question from genuinely low-water or anhydrous products. A category label alone does not prove low risk.
- Packaging and use: jars, open-neck bottles, refill systems, wet-use environments and repeated finger contact can change contamination exposure. A protective dispenser can reduce exposure but does not by itself waive evidence.
- Target market and assessor: market rules, retailer requirements and the safety professional responsible for the file determine what justification and report are acceptable.
- Formula maturity: screens can guide development candidates; a market-file study should identify the intended formula version, batch and sample condition.
- Change control: changes to the preservative system, pH, raw-material grade or supplier, fragrance, process or pack need a documented relevance review and may require new work.
Why two "challenge test" quotes may not be comparable
A cosmetic challenge test deliberately introduces microorganisms into a product sample and follows whether the preservative system controls them. That description fits several different services. Laboratories differ in which method they run, how they challenge the sample, how results are grouped, which method checks they include and what the report is meant to support.
So a lower price is not automatically a bargain, and a higher one is not automatically padding. The price difference often reflects a difference in scope. Until both proposals are written against the same questions, you are comparing labels, not deliverables.
A named example: one laboratory's screen and its full study
Microchem Laboratory publishes both kinds of service, which makes the difference easy to see. Its preservative challenge screen is described as an early indicator during development, with bacterial challenges pooled together and fungal challenges pooled separately. The same laboratory describes a separate USP <51> preservative challenge service that reports individual challenge results and includes validation that organisms can be recovered from the product if they are present.
That is one laboratory's design. It does not mean every screen pools organisms, that every full study looks the same, or that USP <51> and ISO 11930 are equivalent. Other laboratories, such as Intertek, describe preservative efficacy testing to named standards including ISO 11930 and USP methods, with documented results and interpretation, and stress that the method and its applicability matter. The point for a buyer is narrower: ask each laboratory to describe its own service against the same scope questions. These laboratories are cited as public examples, not as GZ partners.
ISO 11930 vs USP <51>: Questions for Your Assessor
ISO 11930:2019 and USP <51> Antimicrobial Effectiveness Testing are different named methods in different standards contexts. The ISO summary describes preservation efficacy testing and evaluation of overall antimicrobial protection for cosmetic products that are not classified as low microbiological risk; the USP page identifies chapter <51> in its compendial context. This buyer-level comparison does not reproduce either protocol or its acceptance criteria. The laboratory and safety assessor should justify the method for the product, market and evidence file.
| Question | ISO 11930 | USP <51> | What the buyer confirms |
|---|---|---|---|
| Primary context | A reference method and evaluation framework developed for the antimicrobial protection of cosmetic products | A compendial antimicrobial effectiveness test applied to specified product categories | Why this method fits the product and intended market file |
| Acceptance framework | Criteria and evaluation follow the named standard and the agreed product assessment | Criteria depend on the compendial product category and method | Which category and criteria the laboratory will report, without assuming the methods are interchangeable |
| Product suitability | The laboratory must address whether the method can recover organisms from this product | Product-specific method suitability and recovery still matter | How neutralisation and recovery are demonstrated and documented |
| Report boundary | Reports on the identified sample under the agreed method | Reports on the identified sample under the agreed method | Sample identity, deviations, results, criteria and signatory; neither report is market approval |
Preparing a formula-led ODM development project?
Share the formula stage, target market, pack and the scope requested by your laboratory or assessor. We can align development versions and manufacturing records; any external method, laboratory and report remain separately agreed.
Scope comparison: screen vs full named-method study
Use the table below to set out what each proposal is offering. The answers shown are what a buyer should expect to be able to write down, not a description of any particular laboratory.
| Scope question | Development screen | Full named-method study |
|---|---|---|
| Purpose of the work | Rank or sanity-check preservative options while the formula can still change | Produce a report on a defined product version that the safety assessor can consider |
| Method and deviations | An identified screening method or provider design, with any referenced standard and the differences from it explained | A named method agreed in writing, with any deviation stated in the proposal and the report |
| Sample and formula maturity | Development samples; several candidates may be tested side by side | A defined version representative of the intended product and process, identified by formula and batch; submission container and any laboratory repacking agreed explicitly |
| How results are presented | Possibly grouped, for example pooled challenges, depending on the laboratory's design | As the named method requires; ask whether results are reported per challenge organism |
| Method suitability and recovery checks | Ask which checks are included, how they fit this product and what limitations remain; do not infer scope from the word screen | Ask how the laboratory demonstrates that organisms can be recovered from this product, and who interprets that check |
| Report delivered | A development-focused report whose promised detail and limitations are stated; report length alone does not define a screen | Full report with sample identity, method, any deviations, results, criteria applied and signatory |
| Where the result can be used | Choosing which candidate to take forward; deciding whether a full study is worth commissioning yet | As one input to the safety assessment and market file for that product version, as judged by the assessor |
If a proposal cannot fill a row, ask before you accept it. A one-line "pass" with no named method, sample identity or criteria tells you very little, whatever the price.
What Affects Preservative Challenge Test Cost and Turnaround?
There is no responsible universal price or duration to quote without a product and a written scope. Compare proposals using the factors below and ask what happens when suitability work, a failed screen or a changed sample adds work.
| Scope factor | Question to put in the request | Why it can change cost or timing |
|---|---|---|
| Named method | Which method, product category and acceptance criteria will be used? | Different methods and categories require different study designs and reporting |
| Screen or full study | Is this a development comparison or a full named-method report? | Screens and full studies answer different questions and include different controls |
| Formula count | How many candidates, variants or packs are separate samples? | Each distinct sample may need its own preparation, tracking and result set |
| Organisms and timepoints | Which challenge organisms and reading points are included by the named method? | The agreed panel and observation schedule determine laboratory work and elapsed time |
| Neutralisation and recovery | How will product-specific method suitability be demonstrated? | Additional development may be needed when the product interferes with recovery |
| Replicates | What repeat or replicate work is included and why? | More samples and measurements increase laboratory work; the provider should justify the design |
| Report interpretation | Will the report include criteria, deviations, limitations and a signed interpretation? | A development note and a complete signed report are different deliverables |
| Retest policy | What happens after a failed suitability check, formula change or out-of-criteria result? | Repeat work is not automatically included and should be agreed before commissioning |
The neutralisation and recovery question
Antimicrobial activity can carry over into the recovery stage. If that residual activity is not addressed by the testing method, organisms still present in the sample can fail to grow in the count, and the product can look better preserved than it is. Microchem's USP <51> description makes this point: the study needs to show it can recover organisms if they are there, rather than mistaking continued antimicrobial effect for their absence.
This is a professional method question, not something a buyer should try to design. What you can do is ask, in writing:
- How will you show that the recovery method works for this specific product, not only for products in general?
- Is that check included in this proposal, and will it appear in the report?
- Has the product type, for example an oil-rich, powder or strongly antimicrobial formula, caused recovery problems before, and how would you handle that?
- If the recovery check fails, what happens to the study, the timeline and the cost?
The laboratory decides the approach and interprets the result. The buyer's role is to make sure the question is in scope and the answer is in the report.
Illustrative proposal comparison
The following is an illustrative proposal comparison, not a real quotation, client or test result. No prices or data are implied.
A brand developing a leave-on body lotion receives two proposals for the same product line. Proposal A covers an early screen on two development candidates with different preservative systems. Proposal B covers a full study to a named method on the frozen formula in its intended pump bottle. Proposal A is much cheaper, and someone asks why the brand would pay more for B.
The price gap does not settle it, because the proposals are for different jobs. Proposal A tests two development versions that will not both be launched, reports grouped results and is meant to steer the formula choice. Proposal B tests the launch version, follows an agreed method and is meant to sit in the safety file. Neither is overpriced or underpriced on that evidence alone.
Before deciding, the buyer asks both laboratories to confirm in writing:
- Which method each proposal follows, and any deviations
- Which formula version and batch will be tested, and in which pack
- Whether results will be grouped or reported per challenge organism
- Whether a product-specific recovery check is included
- What the report will contain and who signs it
- What the laboratory says the result can and cannot be used for
For this illustrative project, the team could choose both in sequence, subject to professional advice: the screen to narrow candidates, then the agreed full study on the selected product version. That sequence is an option, not a requirement for every cosmetic project. What the brand avoids is filing Proposal A's report as if it were Proposal B's. The submission pack is also not proof that the pump system itself has been evaluated: ask which container the method actually uses, and keep packaging-compatibility evidence separate.
What a screen result can support next
A favourable screen is a reason to move forward, not a finished answer. It can help the formulator and the brand decide which candidate to stabilise, whether the preservative system needs adjustment before more money is spent, and when a full study is worth commissioning.
An unfavourable screen can expose a development concern before the team commits to the launch version; whether it avoids cost depends on the project. Either way, take the result back to the formulator and, where relevant, the safety assessor, and let them decide the next step.
What "full study" does not mean
In this article "full" describes the agreed method and scope being complete. It does not mean:
- a complete safety assessment of the product
- approval to place the product on any market
- that every market, retailer or product type requires the same method
- that the product is protected against every way a consumer might contaminate it
A challenge test is a controlled laboratory challenge. Day-to-day contamination in use also depends on the pack, the dispenser and how people use the product, which is why packaging and stability evidence are separate questions. Our stability testing guide covers how those reports are read; this article does not replace it. Whether your product needs a challenge test at all, and to which method, is for your safety assessor and the rules of each market. FDA, for example, says neither US law nor FDA regulations prescribe specific safety tests for individual cosmetics, so a full study is not a universal US checklist item either.
When production changes the evidence
A challenge result describes the version that was tested. A change of preservative, a different grade or supplier of a key raw material, a pH adjustment, a new fragrance or a switch from jar to pump can all affect whether the result still applies.
That does not make every earlier report automatically invalid, and it does not mean the report can be carried forward without thought. Ask the laboratory and the safety assessor for a documented relevance review of each change, and agree with your manufacturer that such changes are notified before production, not after.
Who Owns Each Part of the Evidence?
A challenge study is only as reliable as the link between the submitted sample, the laboratory scope and the product sold. Agree the responsibilities below before samples move.
| Party | Owns or confirms | Must not be assumed |
|---|---|---|
| Brand | Target markets, product brief, intended claims, commercial version and acceptance of the evidence plan | That the cheapest quote answers the launch question |
| Manufacturer | Formula and batch identity, sample traceability, development or production change records and manufacturing documents within scope | That the manufacturer is the external testing laboratory or the safety assessor |
| External laboratory | Method, suitability and recovery approach, deviations, results, criteria, report and signatory within its agreed scope | That a report is market approval or a complete safety assessment |
| Safety assessor or Responsible Person | Whether the evidence is relevant and sufficient for the product and market file, and whether changes require further work | That a screen can be treated as a full study without review |
In an ODM development project, screens can support formula iteration before the launch version is locked. In an OEM manufacturing project, the main role is version and batch traceability for a formula already defined. We do not describe GZ Cosmetics Lab as a third-party microbiology laboratory or safety assessor. Our quality and testing page explains the boundary between manufacturing controls and separately scoped external work.
Where an external challenge study is needed, the method, laboratory, sample, cost and report are confirmed per project in writing; no particular partnership or result is promised. When you know the product, pack and target markets, send the development brief so we can clarify the records we provide and the questions that remain with the external laboratory or professional adviser.
Frequently asked questions
Is a challenge screen worthless?
No. A screen is useful during development for comparing candidates and catching weak preservative systems early. It simply is not the same deliverable as a full named-method study, and its report should not be presented as one.
Is ISO 11930 the same as USP chapter 51?
No. They are different named methods. Ask your laboratory and safety assessor which method fits your product and market, and do not assume one report satisfies a requirement written around the other.
Does a full challenge study mean the product is ready to launch?
No. It is one input to the safety assessment. Launch also depends on the rest of the safety file, labelling and each market's obligations.
Do we need a new challenge test after every formula change?
Not automatically. Ask for a professional relevance review of the change and record the decision. Some changes may need new work; others may be justified on existing evidence.
How much does preservative challenge testing cost?
There is no universal price. The named method, screen or full-study scope, number of formulas, method-suitability work, organisms and timepoints, replicates, report detail and retest policy all affect the quotation. Compare written scopes rather than headline prices.
How long does a cosmetic challenge test take?
The elapsed time follows the agreed method and its reading schedule, plus sample intake, suitability work and reporting. A development screen may use a different schedule from a full named-method study. Ask the laboratory for milestones and what could trigger a restart; do not plan launch from a generic duration.
Who should perform a preservative challenge test?
A competent laboratory with a method, personnel and quality scope appropriate to the product should perform and report the study. The brand and manufacturer identify the sample and intended use; the laboratory owns the method and results; the safety assessor or Responsible Person decides how the report fits the market evidence file.
Ready to Start Your Project?
Tell us your product requirements. Within 24 hours, our technical team will reply with a quotation or the questions needed to prepare one.